Currently, combination therapy of anti-PD-L1 and IPI-549 is being explored as a treatment for patients with triple-negative breast cancer and renal cell carcinoma [57] and might prove effective in patients with poorly immunogenic HNSCC in the future. This evidence concerns the gene CD274 and renal cell carcinoma.